Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on oncology and obesity, will participate in a virtual fireside chat at UBS Obesity Therapeutics Day on May 23, 2024. The event, which will include members of Terns' senior management, will be webcast live at 1:00 p.m. ET and archived for 30 days on their investor relations page.
- Terns Pharmaceuticals' participation in UBS Obesity Therapeutics Day can enhance visibility among potential investors and industry peers.
- The webcast provides an opportunity for transparency and direct communication with stakeholders.
- Archiving the webcast for 30 days allows for extended access and engagement.
- The announcement lacks specific updates on clinical trials or financial performance, which may leave investors seeking more substantial information.
- No immediate impact on revenue or earnings is indicated from the participation in the event.
- The webcast's effectiveness in influencing stock performance is uncertain without follow-up on actionable outcomes.
FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a virtual fireside chat at UBS Obesity Therapeutics Day on Thursday, May 23, 2024 at 1:00 p.m. ET.
A live webcast of the fireside chat will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the event.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
When will Terns Pharmaceuticals participate in UBS Obesity Therapeutics Day?
What time is the Terns Pharmaceuticals fireside chat at UBS Obesity Therapeutics Day?
Where can I watch the Terns Pharmaceuticals webcast for UBS Obesity Therapeutics Day?
Will the Terns Pharmaceuticals webcast be available after the live event?
